Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas

Cells. 2023 Nov 20;12(22):2656. doi: 10.3390/cells12222656.

Abstract

In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.

Keywords: atezolizumab; brentuximab vedotin; lacutamab; lymphomatoid papulosis; mogamulizumab; mycosis fungoides; nivolumab; pembrolizumab; primary cutaneous anaplastic large T-cell lymphoma; tagraxofusp.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents* / therapeutic use
  • Brentuximab Vedotin / therapeutic use
  • Humans
  • Mycosis Fungoides* / pathology
  • Sezary Syndrome* / pathology
  • Skin Neoplasms* / pathology

Substances

  • Brentuximab Vedotin
  • Antineoplastic Agents
  • Antibodies, Monoclonal

Grants and funding

This research received no external funding.